LUND UNIVERSITY

Can dressings soaked with polyhexanide reduce bacterial loads in full-thickness skin grafting? A randomized controlled trial

Saleh, Karim; Sonesson, Andreas; Persson, Kerstin; Riesbeck, Kristian; Schmidtchen, Artur

Published in:
Journal of the American Academy of Dermatology

DOI:
[10.1016/j.jaad.2016.07.020](https://doi.org/10.1016/j.jaad.2016.07.020)

2016

Document Version:
Peer reviewed version (aka post-print)

[Link to publication](#)

Citation for published version (APA):
Saleh, K., Sonesson, A., Persson, K., Riesbeck, K., & Schmidtchen, A. (2016). Can dressings soaked with polyhexanide reduce bacterial loads in full-thickness skin grafting? A randomized controlled trial. *Journal of the American Academy of Dermatology*, 75(6), 1221-1228.e4. <https://doi.org/10.1016/j.jaad.2016.07.020>

Total number of authors:
5

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Can dressings soaked with polyhexanide reduce bacterial loads in full-thickness skin grafting? A randomized controlled trial.

Karim Saleh, MD^{1*}, Andreas Sonesson, MD, PhD¹, Kerstin Persson, BS¹, Kristian Riesbeck, MD, PhD², Artur Schmidtchen, MD, PhD^{1,3}

¹Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden

²Clinical Microbiology, Department of Translational Medicine, Lund University, Malmö, Sweden

³LKC Medicine, Nanyang Technological University, Singapore

*Correspondence: Division of Dermatology, Department of Clinical Sciences, Biomedical Center B14, Lund University, Tornavägen 10, SE-221 84 Lund, Sweden. Tel: +46 46 222 33 15. Fax: +46 46 15 77 56. Email: Karim.Saleh@med.lu.se

Word counts

Abstract: 240

Capsule summary: 65

Text: 2447

Number of references: 32

Tables: 1

Figures: 2

Supplementary tables and figures: 3

Ethical approval was granted by the ethical committee in Malmö/Lund, registration number (2013/762).

Registered at www.clinicaltrials.gov. **ClinicalTrials.gov Identifier:** NCT02253069

This article was funded by the program "Innovation mot infektion" (IMI), financed by the VINNOVA- Swedish governmental agency for innovation systems, the Swedish Government Funds for Clinical Research (ALF), and The Swedish Research Council (2012-1883).

Dr. Schmidtchen has received consulting support from Mölnlycke Health Care AB.

49 **ABSTRACT**

50 **Background:** Polyhexamethylene biguanide (PHMB)-based antiseptic solutions can
51 reduce bacterial loads in different clinical settings and are believed to lower risk of
52 infections.

53 **Objective:** To assess the efficacy of a PHMB-based solution in lowering bacterial
54 loads of full-thickness skin grafting (FTSG) wounds and the risk of SSIs.

55 **Methods:** In this double-blinded clinical trial, 40 patients planned for facial FTSG
56 were randomized 1:1 to receive tie-over dressings soaked with either PHMB-based
57 solution or sterile water. Quantitative and qualitative bacterial analysis was performed
58 on all wounds before surgery, at the end of surgery, and 7 days postoperatively. In
59 addition, all patients were screened for nasal colonization of *S. aureus*.

60 **Results:** Analysis of wounds showed no statistically significant difference in bacterial
61 reductions between the groups. The SSI rates were significantly higher in the
62 intervention group (8/20) than in the control group (2/20) ($P=.028$). Higher
63 postoperative bacterial loads were a common finding in SSIs ($P=.011$). This was more
64 frequent when *S. aureus* was present postoperatively ($P=.034$), intraoperatively
65 ($P=.03$), and in patients with intranasal *S. aureus* colonization ($P=.007$).

66 **Limitations:** Assessment of SSIs is largely subjective. In addition, this was a single-
67 center study and the total number of participants was 40.

68 **Conclusion:** Soaking tie-over dressings with PHMB-solution in FTSG had no effect
69 on postoperative bacterial loads and increased the risk of SSI development. The
70 presence of *S. aureus* intranasally and in wounds preoperatively and postoperatively
71 increased postoperative bacterial loads, which in turn resulted in significantly more
72 SSIs.

73

74 Key words: Surgical site infections; dermatologic surgery; pathogenesis; prevention;
75 wound infection; bacteria; *S. aureus*

76

77 Classifications:

78 212: Bacterial infections

79 790: Evidence-based medicine

80 1239: Infection

81 1660: Microbiology

82 2170: Prevention

83 2520: Surgery

84 2780: Wounds & wound healing

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99 Capsule summary:

- 100 • PHMB as an antiseptic has gained popularity in different clinical settings but
101 hasn't yet been studied in full-thickness skin grafting (FTSG).
- 102 • This trial showed that adding PHMB to tie-over dressings had no effect on
103 reducing bacterial loads in wounds and resulted in more surgical site
104 infections.
- 105 • Use of PHMB in FTSG as a method to prevent SSIs is questionable, and
106 further clinical studies are warranted.

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124 INTRODUCTION

125 Polyhexamethylene biguanide (PHMB) is a polymer used as a disinfectant and
126 antiseptic.¹⁻⁶ In recent years, it has gained popularity and has been used safely in
127 different clinical settings such as in intraoperative irrigation during nail surgery¹,
128 treatment of burns⁵, orthopedic surgery antiseptics⁶, wound dressings³, prevention of
129 infections in peritoneal catheters⁴, and in combination with negative-pressure wound
130 therapy (NPWT) where it has been shown to be better than NPWT alone in treating
131 infected wounds.⁷

132

133 The advantages of PHMB include broad antibacterial activity, good cell and tissue
134 tolerability, low risk of contact sensitization, promotion of wound healing, and no
135 development of bacterial resistance.² In addition to having an effect on Gram-
136 negative bacteria⁸, it also has effects against methicillin-resistant *Staphylococcus*
137 *aureus* (MRSA).⁹ The microbicidal effect of PHMB is comparable to that of
138 chlorhexidine¹⁰, but does not contain the toxic substituents found in chlorhexidine.¹¹

139

140 In this study we investigated whether a PHMB-based antiseptic solution added to tie-
141 over dressings used in full-thickness skin grafting (FTSG) could reduce bacterial load
142 of wounds. This is a factor believed to have a role in the development of surgical site
143 infections (SSIs) as previously published by our group.¹² We hypothesized that a
144 reduction in the bacterial load would lower the risk of SSIs. We were also interested
145 in examining the presence of *S. aureus* intranasally and wanted to study its relevance
146 for SSIs. Recent studies have indicated that nasal colonization with *S. aureus* is an
147 important risk factor for development of SSIs.¹³⁻¹⁵ By analyzing bacterial quantities

and species at different stages of surgery, we sought to improve our understanding of the development of SSIs and its complex pathogenesis.

METHODS

Study Design

We conducted this prospective, double-blinded, randomized, placebo-controlled trial between September 2014 and September 2015 at Lund University Hospital, Sweden. This single-center study was approved by the ethical committee in Malmö/Lund, registration number (2013/762) and registered with ClinicalTrials.gov (NCT02253069). All patients over age 18 planned for facial FTSG were allowed to participate in the trial. We limited inclusion to surgery localized to the face because bacterial loads are known to vary from one anatomical site to another.¹⁶ All grafts were harvested from the neck region. Exclusion criteria were diabetes, treatment with antibiotics within the last four weeks prior to surgery, and planned antibiotic therapy. Written informed consent was obtained from all patients before enrollment. The same nurse prepared all patients for surgery, which included using a 0.5% chlorhexidine solution for preoperative skin preparation. Four dermatologists performed surgery under routine sterile conditions. One principal investigator was in charge of collecting bacterial samples and assessing wounds postoperatively.

Power analysis and randomization

In a previous *in vitro* study, a reduction of $>5 \log_{10}$ was achieved with a concentration of 0.02% PHMB against *S. aureus*.¹⁰ We hypothesized that application of 0.1% PHMB as found in the commercially available Prontosan[®] Wound irrigation solution (B. Braun Medical, Switzerland) would at least reduce bacterial load in wounds by

half versus placebo. To get 80% power with an α -value of 0.05, it was calculated that 16 patients were required in each group. By including 20 patients in each group in this trial to allow for dropouts, noticeable differences in bacterial reduction would be detected. Patients were randomized according to a list generated using QuickCalcs (www.graphpad.com/quickcalcs).

***In vitro* antibacterial assay**

Prior to this trial, *in vitro* experiments were performed to assess antibacterial activity of PHMB. See Supplementary Methods.

Intervention

At the end of each surgery, once the skin graft had been sutured to the wound, a tie-over dressing was cut from Mepilex[®]. It was then soaked with either Prontosan[®] solution or sterile water (see Supplementary Methods for details) according to the randomization protocol.

Follow up

All patients were planned for a single follow up 7 days after surgery. Skin grafts were assessed in terms of redness, edema, discharge, graft take, and pain resulting in an overall assessment by the blinded principal investigator classifying a wound as "infected" or "non-infected". No scoring system was used for this purpose. Digital photographs were taken of all wounds pre- and postoperatively.

Bacterial load analysis

Bacterial samples were blindly collected from each patient using Eswabs (Copan, Brescia, Italy). Swabs were taken in a controlled manner by swabbing in a circular motion for 10 seconds. This was done at 3 different phases. Before surgery (BS) prior to antisepsis, the skin area containing the suspected neoplasm planned for excision was swabbed to establish the starting bacterial load level. Next, at the end of surgery (ES), the skin graft sutured to the wound was swabbed to establish a second starting load level. A final swab was taken from the wound one week after surgery (1W) after removal of the tie-over dressing.

Each swab was analyzed quantitatively by counting CFU per cm² of area swabbed as well as the type of bacteria present. Bacterial quantification was done by serially diluting each swab to 3 different concentrations plating each concentrate onto a Todd-Hewitt agar plate using sterile glass beads and incubating all plates in 5% CO₂ at 37°C for 24 h. The CFU were then counted and were usually between 30 and 300 CFUs. The CFU was divided with the swab area to measure bacterial loads in CFU/cm². Bacterial species were determined via matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.

Intranasal swabs

Before surgery, an Eswab was rotated in the patient's naris that was closest to the neoplasm planned for excision. Typing was performed using MALDI-TOF to detect presence of *S. aureus*. No quantification was done on these swabs.

Statistics

Statistical analyses were performed with SPSS v.22 software (SPSS Inc., Chicago, IL). Bacterial load reduction was determined by using the following formulas:

CFU(1W)-CFU(BS), CFU(1W)-CFU(ES), CFU(1W)/CFU(BS), and CFU(1W)/CFU(ES). All median values obtained were compared using a Mann-Whitney U test to examine if differences existed between the groups. Differences in categorical variables were determined using the chi-square test. Differences in continuous variables were estimated using Student's *t* test. Statistical significance was set at $P < .05$.

Outcome measures

Our primary measure was to compare bacterial load reductions in both groups. The development of SSIs was a secondary outcome in this trial, and the tertiary outcome was the intranasal presence of *S. aureus* and examining its relevance for the bacterial dynamics of surgical wounds.

RESULTS

Our *in vitro* trials showed that only dressings soaked with PHMB inhibited growth of both *S. aureus* and *S. epidermidis* (Supplementary Figure 1). This was in accordance with previously published studies demonstrating antibacterial properties of PHMB against various skin bacteria.¹⁷⁻²⁰ As for this trial, there were no significant differences in patient characteristics in each group in terms of age, sex, wound location, and tumor excised (Supplementary table 1). Most wounds were located on the nose, which is known to be the most common site of skin malignancies.²¹ No significant differences were noted among the groups in bacterial load levels measured before surgery, at end of surgery, and after one week. (Supplementary Table 2). No significant differences were detected between the groups in terms of bacterial reduction via the four calculations described in Methods (Supplementary Table 2).

247

248 A total of 10 wounds were assessed as infected to give an overall SSI rate of 25% in
249 this study. Eight of these wounds belonged to the intervention group, which had a
250 statistically higher rate of infection (chi-square 4.8, $P=.028$). Statistical analyses
251 showed that patient characteristics such as gender, age, and wound location did not
252 correlate to SSI rates in this study. All patients with SSIs had a significantly higher
253 bacterial load measured postoperatively after one week as illustrated in Figure 1A.
254 When *S. aureus* was isolated from wounds postoperatively after one week, patients
255 had a significantly higher bacterial load (Figure 1B). The presence of *S. aureus*
256 intranasally before surgery was also associated with a higher postoperative bacterial
257 load (Figure 1C). Whether coagulase-negative staphylococci (CoNS) were isolated
258 from wounds postoperatively or not had no effect on postoperative bacterial loads,
259 although a higher spread in the total CFUs was observed (Figure 2A). The presence of
260 *S. aureus* at the end of surgery in patients resulted in significantly higher
261 postoperative bacterial loads (Figure 2B).

262

263 Typing of all strains isolated from swabs revealed that CoNS and *S. aureus* were the
264 predominant species (Table 1). The number of species successfully isolated from all
265 patients was highest in the swabs before surgery (27 different species) and lowest
266 one week after surgery (8 species). Four out of 10 infected wounds contained *S.*
267 *aureus*.

268

269 **DISCUSSION**

270 SSIs in dermatologic surgery result in unnecessary health costs as well as added pain,
271 discomfort, and dissatisfactory cosmetic outcomes for patients.^{22,23} Furthermore, the

use of preventative measures such as antibiotic prophylaxis, although sometimes warranted, can contribute to the emergence of resistant bacterial strains and give unwanted side effects, such as allergic reactions in patients.²⁴ Effective evidence-based measures are therefore highly needed—especially in FTSG surgery, which is normally associated with a higher rate of SSI.²⁵

In this randomized controlled trial, we tested the efficacy of PHMB in preventing SSIs. Our results show that PHMB had no effect on reducing postoperative bacterial loads. Surprisingly, adding PHMB to tie-over dressings resulted in a significantly higher risk of SSI. Previous studies have shown that applying a certain antibacterial agent locally to wounds can suppress the growth of certain bacterial species, which can cause an overgrowth of other species that might be harmful.²⁶ Although speculative, it is possible that PHMB, by reducing the commensal flora, *i.e.* the microbiome, could give rise to an increased colonization of *S. aureus* or other pathogens. Indeed, there appeared to be a higher spread in the bacterial levels when *S. epidermidis* was absent postoperatively (Fig. 2A), and Gram-negative bacterial species were particularly detected in the PHMB-treated group one week after surgery (Table 1), findings suggestive of possible microbiome changes induced by PHMB. Clearly, the limited number of patients enrolled in this study makes it impossible to draw any firm conclusions on the protective role of commensals and the role of PHMB. However, it is worth noting that the microbiome has recently been attributed with important roles in protection against infections. For example, *Staphylococcus epidermidis* can produce antimicrobials, which can keep potential pathogens at bay.²⁷ *S. epidermidis* can also activate toll-like-receptor-2 (TLR2) signaling and induce

antimicrobial peptide expression, thus enabling the skin to mount an enhanced response to pathogens.^{28,29}

We found 27 different bacterial species before surgery making it impossible to analyze which particular species could be responsible for increasing the risk of SSIs from a statistical point of view. A quantification of each particular species would be necessary to investigate this further. Here, only the total quantity of all bacteria in a swab was measured. Nevertheless, it was interesting to note that the variation of bacterial species was highest prior to surgery and lowest postoperatively in both groups. Yet in 24 out of 40 patients, bacterial loads were higher postoperatively than preoperatively. It appears that certain species exhibits a stronger tendency to grow directly after surgery. Further studies in larger patient groups are needed to verify this observation. Another result was that the bacterial species observed here agreed well with previously published studies showing that most frequently isolated species from wounds are *S. aureus* and CoNS.³⁰

In this trial, we established two different starting bacterial loads due to the nature of FTSG surgery where skin is moved from one anatomical site to another. Comparing postoperative bacterial loads present on a graft to the presurgical swab taken on anatomically different skin would be unfair. We therefore compared the postoperative bacterial loads levels with the levels observed before and at end of surgery. Our analyses showed that the PHMB-based dressing had no effect on reducing postoperative bacterial loads. Indeed, there was actually a tendency towards higher loads one week after surgery in the intervention group compared to the control group. The extensive variety of bacterial species found preoperatively (27 different species)

is yet another interesting finding. We could only compare these data to the variety present postoperatively (8 different species). Thus, this difference could again be attributed to the anatomical skin flora variations *per se* at the donor sites or to the microbiome and host defense changes as mentioned above. Another theory in line with a recent publication³¹ is that the presence of a neoplasm in the swab taken preoperatively is somehow related to a high bacterial variety.

We validated our previously published findings¹² and showed that a total postoperative bacterial load correlates positively to wound infection. Furthermore, postoperative bacterial loads were shown to be significantly higher when *S. aureus* was present in wounds intra- and postoperatively as well as in patients who had a nasal colonization with *S. aureus* detected prior to surgery. However, there was no direct relationship between presence of *S. aureus* in wounds, or intranasally, and SSIs. Still, *S. aureus* appears to continue to be one of the key pathogens involved in the development of SSIs. The presence of CoNS in wounds on the other hand seems to reduce the tendency towards developing an SSI by a reduced postoperative bacterial load. However, this observation was not statistically significant ($P=.08$) as shown in Figure 2a. Although speculative, it is thus possible that an expanded preoperative screening of bacteria present preoperatively—not only in the nares, but also at the surgical site—could aid in the prediction of SSIs. It is also possible that boosting of the "healthy" microbiome—including *S. epidermidis*—could be beneficial for wound healing outcomes and in ongoing *in vitro* based experiments. Thus, we therefore are currently evaluating the effects of both commensal and pathogenic bacteria in skin models.

A limitation of our study is that one of our outcomes (diagnosis of SSIs) was dependent on a subjective assessment of a single investigator. Studies have shown both inter- and intra-observer variations when diagnosing SSIs³². These show the importance of finding a more objective method of diagnosing SSIs in the future. Nevertheless, the SSI scoring was performed in a blinded fashion to avoid potential bias between the groups. Other limitations were that this was a single-center study and that the total number of participants in the study was 40.

CONCLUSION

We used PHMB as a novel disinfectant to prevent SSIs in FTSG. PHMB appeared to increase the risk of SSIs at least in the experimental setting used here. In light of the emergence of new resistant bacterial strains that cause SSIs, there is a need for further research that can define preventative methods to improve outcomes. Measures that lower bacterial loads, prevent *S. aureus* regrowth in wounds and abolish intranasal colonization are important and ongoing.

Acknowledgments

We are greatly indebted to Mina Davoudi, Emma Matsson, Ann-Charlotte Strömdahl, and Dr. Ingrid Siemund for their efforts in conducting the study. We also wish to thank the nursing staff (Eva Jacobsson, Helene Palmqvist, Susanne Erdmann) and Åse Jönsson at our clinic for valuable assistance making this trial possible.

371 Abbreviations used:

372 SSI: Surgical site infection

373 FTSG: Full-thickness skin grafting

374 PHMB: Polyhexamethylene biguanide

375 NPWT: Negative-pressure wound therapy

376 MRSA: Methicillin-resistant *Staphylococcus aureus*

377 CFU: Colony-forming-unit

378 MALDI-TOF: Matrix-assisted laser desorption/ionization time-of-flight

379 TLR2: Toll-like-receptor-2

380 CoNS: Coagulase-negative staphylococcus

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

1. Becerro de Bengoa Vallejo R, Losa Iglesias ME, Cervera LA, Fernandez DS, Prieto JP. Efficacy of intraoperative surgical irrigation with polyhexanide and nitrofurazone in reducing bacterial load after nail removal surgery. *J Am Acad Dermatol* 2011;64:328-35.
2. Eberlein T, Assadian O. Clinical use of polyhexanide on acute and chronic wounds for antisepsis and decontamination. *Skin Pharmacol Physiol* 2010;23 Suppl:45-51.
3. Eberlein T, Haemmerle G, Signer M, et al. Comparison of PHMB-containing dressing and silver dressings in patients with critically colonised or locally infected wounds. *J Wound Care* 2012;21:12, 4-6, 8-20.
4. Nunez-Moral M, Sanchez-Alvarez E, Gonzalez-Diaz I, et al. Exit-site infection of peritoneal catheter is reduced by the use of polyhexanide. results of a prospective randomized trial. *Perit Dial Int* 2014;34:271-7.
5. Piatkowski A, Drummer N, Andriessen A, Ulrich D, Pallua N. Randomized controlled single center study comparing a polyhexanide containing bio-cellulose dressing with silver sulfadiazine cream in partial-thickness dermal burns. *Burns* 2011;37:800-4.
6. Rohner E, Seeger JB, Hoff P, et al. Preferred use of polyhexanide in orthopedic surgery. *Orthopedics* 2011;34:e664-8.
7. Kim PJ, Attinger CE, Steinberg JS, et al. The impact of negative-pressure wound therapy with instillation compared with standard negative-pressure wound therapy: a retrospective, historical, cohort, controlled study. *Plast Reconstr Surg* 2014;133:709-16.
8. Fabry WH, Kock HJ, Vahlensieck W. Activity of the antiseptic polyhexanide against gram-negative bacteria. *Microb Drug Resist* 2014;20:138-43.
9. Rietkotter J, Korber A, Grabbe S, Dissemmond J. Eradication of methicillin-resistant *Staphylococcus aureus* in a chronic wound by a new polyhexanide hydrogel. *J Eur Acad Dermatol Venereol* 2007;21:1416-7.
10. Muller G, Kramer A. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. *J Antimicrob Chemother* 2008;61:1281-7.
11. Hubner NO, Matthes R, Koban I, et al. Efficacy of chlorhexidine, polyhexanide and tissue-tolerable plasma against *Pseudomonas aeruginosa* biofilms grown on polystyrene and silicone materials. *Skin Pharmacol Physiol* 2010;23 Suppl:28-34.
12. Saleh K, Sonesson A, Persson B, Riesbeck K, Schmidtchen A. A descriptive study of bacterial load of full-thickness surgical wounds in dermatologic surgery. *Dermatol Surg* 2011;37:1014-22.
13. Cordova KB, Grenier N, Chang KH, Dufresne R, Jr. Preoperative methicillin-resistant *Staphylococcus aureus* screening in Mohs surgery appears to decrease postoperative infections. *Dermatol Surg* 2010;36:1537-40.
14. Tai YJ, Borchard KL, Gunson TH, Smith HR, Vinciullo C. Nasal carriage of *Staphylococcus aureus* in patients undergoing Mohs micrographic surgery is an important risk factor for postoperative surgical site infection: a prospective randomised study. *Australas J Dermatol* 2013;54:109-14.
15. Cherian P, Gunson T, Borchard K, et al. Oral antibiotics versus topical decolonization to prevent surgical site infection after mohs micrographic surgery--a randomized, controlled trial. *Dermatol Surg* 2013;39:1486-93.

16. Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin microbiome. *Science* 2009;324:1190-2.
17. Kirker KR, Fisher ST, James GA, McGhee D, Shah CB. Efficacy of Polyhexamethylene Biguanide-containing Antimicrobial Foam Dressing Against MRSA Relative to Standard Foam Dressing. *Wounds* 2009;21:229-33.
18. Minnich KE, Stolarick R, Wilkins RG, et al. The effect of a wound care solution containing polyhexanide and betaine on bacterial counts: results of an in vitro study. *Ostomy Wound Manage* 2012;58:32-6.
19. Kamaruzzaman NF, Firdessa R, Good L. Bactericidal effects of polyhexamethylene biguanide against intracellular *Staphylococcus aureus* EMRSA-15 and USA 300. *J Antimicrob Chemother* 2016;71:1252-9.
20. Rembe JD, Fromm-Dornieden C, Schafer N, Bohm JK, Stuermer EK. Comparing two polymeric biguanides: Chemical distinction, antiseptic efficacy and cytotoxicity of Polyaminopropyl biguanide (PAPB) and Polyhexamethylene biguanide (PHMB). *J Med Microbiol* 2016.
21. Janjua OS, Qureshi SM. Basal cell carcinoma of the head and neck region: an analysis of 171 cases. *J Skin Cancer* 2012;2012:943472.
22. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. *JAMA* 2003;290:1868-74.
23. Nestor MS. Prophylaxis for and treatment of uncomplicated skin and skin structure infections in laser and cosmetic surgery. *J Drugs Dermatol* 2005;4:s20-5.
24. Rossi AM, Mariwalla K. Prophylactic and empiric use of antibiotics in dermatologic surgery: a review of the literature and practical considerations. *Dermatol Surg* 2012;38:1898-921.
25. Dixon AJ, Dixon MP, Askew DA, Wilkinson D. Prospective study of wound infections in dermatologic surgery in the absence of prophylactic antibiotics. *Dermatol Surg* 2006;32:819-26; discussion 26-7.
26. Smack DP, Harrington AC, Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. *JAMA* 1996;276:972-7.
27. Christensen GJ, Bruggemann H. Bacterial skin commensals and their role as host guardians. *Benef Microbes* 2014;5:201-15.
28. Lai Y, Cogen AL, Radek KA, et al. Activation of TLR2 by a small molecule produced by *Staphylococcus epidermidis* increases antimicrobial defense against bacterial skin infections. *J Invest Dermatol* 2010;130:2211-21.
29. Gallo RL, Nakatsuji T. Microbial symbiosis with the innate immune defense system of the skin. *J Invest Dermatol* 2011;131:1974-80.
30. Saleh K, Schmidtchen A. Surgical site infections in dermatologic surgery: etiology, pathogenesis, and current preventative measures. *Dermatol Surg* 2015;41:537-49.
31. Hoste E, Arwert EN, Lal R, et al. Innate sensing of microbial products promotes wound-induced skin cancer. *Nat Commun* 2015;6:5932.
32. Bruce J, Russell EM, Mollison J, Krukowski ZH. The quality of measurement of surgical wound infection as the basis for monitoring: a systematic review. *J Hosp Infect* 2001;49:99-108.

Figure 1. Postoperative bacterial loads after one week shown for each patient group (controls and PHMB) or all patients combined. (A) Differences between wounds classified as infected and non-infected. (B) Differences in regard to presence of *S. aureus* in wounds at one week after surgery. (C) Levels correlated to presence of *S. aureus* intranasally. Outliers in all plots are indicated by an asterisk (*). Solid bars depict interquartile range and the hash marks show the total range. A difference in median CFU/cm² (calculated using Mann-Whitney's test) with a *P* value of <.05 is regarded as statistically significant.

A

B

Figure 2. Bacterial loads at one week after surgery measured in all patients whether (A) CoNS were isolated postoperatively and whether (B) *S. aureus* was isolated at end of surgery. The outliers were expressed with an asterisk (*). Solid bars depict interquartile range and the hash marks show the total range. Calculations of median CFU/cm² values using a Mann-Whitney test with a *P* value of <.05 were regarded as statistically significant.

[illegible]

541

543 ■ *S. epidermidis*544 ■ *S. hemolyticus*545 ■ *S. lugdunensis*

546 ■ Other CoNS

547 ■ *S. aureus*

548 ■ Gram-negative species

549 ■ *Corynebacterium* species

550 ■ Acinetobacter species

551 ■ Bacillus

552 ■ Streptococci

553 ☐ No growth

554

555

542

556

557

558

559

560

561

562

563

564

565

566

567

Table 1. Bacterial species isolated before surgery (BS), after one week (1W), and intranasally (Nasal). Each row represents a patient. An asterisk (*) in the beginning of each row indicates patients developing an SSI.

571

572

573

574

575

576

577 SUPPLEMENTARY DATA

578

579 METHODS

580

581 ***In vitro* antibacterial assay**582 Todd-Hewitt (TH) agar plates were streaked with *S. aureus* ATCC 29213 and *S.*583 *epidermidis* ATCC 14909. Each plate contained 1×10^5 colony-forming units (CFU).584 Eight mm polyurethane dressings (Mepilex[®], Mölnlycke Healthcare, Göteborg,585 Sweden) soaked with Prontosan[®] solution or sterile water were applied on top to586 simulate an *in vivo* situation where the dressing is applied onto a wound.

587 The dressings were soaked with 70% of the solution, where 100% was considered as

588 the maximum wetting capacity of the dressing. 70% wetting was also to be used in

589 this patient trial. The zone of inhibition around the discs was measured.

590

591 **Preparation of Mepilex[®] dressings**

592 Prior to surgery, seven circular dressing templates with varying diameters ranging

593 from 10 mm to 34 mm were cut from Mepilex[®]. Necessary liquid volume to achieve

594 70% wetting was calculated by subtracting each template's fully saturated weight

595 from its dry weight and multiplying the result by 0.7. For each dressing template, 20

596 test tubes were prepared containing sterile water and 20 test tubes contained

597 Prontosan[®] solution. These were marked with either A or B by an external

598 investigator not involved in this trial and blinded to the nurse, surgeon, and principal

599 investigator. Prontosan[®] solution is like water both colorless and odor-free. The600 dressing templates were used for proper determination of the volume of Prontosan[®] or

601 sterile water required for wetting tie-over dressings used during surgery.

602

FIGURES

A

B

Figure 1. *In vitro* antibacterial assays illustrating measured inhibition zones of dressings soaked with water (control) or PHMB on agar plates coated with 1×10^5 CFU of (A) *S. aureus*, and (B) *S. epidermidis* (n=3, bar indicates S

612

Item	Intervention group	Control group	<i>P value</i>
Age			.351
Range	47-92	45-91	
Mean $\pm$ SD	74.45 $\pm$ 12.05	78.20 $\pm$ 13.05	
Median	74	85	
Sex, n (%)			.204
Male	11	7	
Female	9	13	
Wound location			.216
Nose	13	10	
Cheek	1	5	
Temple	3	1	
Forehead	2	2	
Ear	0	2	
Scalp	1	0	
Tumor excised			.435
BCC	15	15	
SCC	3	1	
Other	2	4	

613 BCC: Basal cell carcinoma. SCC: Squamous cell carcinoma.

614

615 **Table 1.** Patient characteristics and selected baseline values.

616

617

618

619

620

621

622

	Intervention Group	Control Group	<i>P</i> value
Median BS (CFU/cm ²)	10640.50	12180.50	.752
Median ES (CFU/cm ²)	13	13	.751
Median 1W (CFU/cm ²)	64132.50	23425.50	.752
Change (ES-1W)	5668.15	779	.608
Change (BS-1W)	2.7	1.1	.150
Difference 1W minus ES	64105.50	23415.50	.752
Difference 1W minus BS	28903.50	204.50	.343

623

624 **Table 2.** Bacterial quantification of all swabs taken before surgery (BS), at
625 end of surgery (ES), and after one week (1W).